News for Opthea Limited (OPT)

The ASX has been up, charging 4.7% higher at around 7,720 points…

**media[580863]**

Good Afternoon and welcome to HotCopper Highlights, I’m Jonathon Davidson. This is where we highlight what you were watching and discussing most on the forums this week. Let’s get into it.

Immutep Ltd has dosed the first patient of its Phase 3 TACTI-004 non-small cell lung cancer trial in its final stage of clinical study.

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results und

**media[574270]**

It mightn't be too surprising that Opthea applied for a voluntary suspension last week ahead of Monday's Phase 3 trial results.

Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Reti

Cash and cash equivalents of $131.9M as of December 31, 2024 Cash runway extends through anticipated topline data readouts of COAST (early 2Q CY25) and ShORe (

Three consecutive commercial-scale drug product batches successfully produced Supports potential sozinibercept BLA filing in 1H CY2026 MELBOURNE, Australia

COAST Phase 3 trial evaluates superiority and safety of sozinibercept combined with aflibercept in wet AMD Company confirms topline results for COAST a

We recently compiled a list of the 10 Best Long Term ASX Stocks to Buy Now. In this article, we are going to take a look at where Opthea Limited (NASDAQ:OPT) stands against the other long term ASX stocks...

**media[534928]**

MELBOURNE, Australia and PRINCETON, N.J., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/OPT, ”œOpthea”, the ”œCompany”), a clinical-stage biopha

We recently compiled a list of the 10 Best ASX Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Opthea Limited (NASDAQ:OPT) stands against other best ASX...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm neutral on OPT stock.

**media[509148]**

**media[507938]**

Phase 1b clinical data underpins sozinibercept's potential as a novel, first-in-class VEGF-C/D ”˜trap' to improve visual and anatomic outcomes in DME Publis